Gyre Therapeutics, Inc.
GYRE
$6.13
$0.081.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.36M | 5.03M | 6.65M | 4.17M | 7.25M |
| Total Depreciation and Amortization | 2.66M | 2.52M | 2.33M | 2.12M | 1.71M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.23M | 11.72M | 7.25M | 6.26M | 5.82M |
| Change in Net Operating Assets | -3.21M | -18.26M | -12.35M | -11.61M | -21.44M |
| Cash from Operations | 4.32M | 1.01M | 3.88M | 927.00K | -6.65M |
| Capital Expenditure | -1.25M | -1.19M | -981.00K | -1.01M | -2.21M |
| Sale of Property, Plant, and Equipment | 35.00K | 30.00K | 157.00K | 152.00K | 352.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.29M | 686.00K | -3.50M | -4.61M | -8.84M |
| Cash from Investing | -5.50M | -474.00K | -4.33M | -5.47M | -10.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 24.42M | 25.87M | 26.88M | 27.20M | 3.45M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.37M | -1.49M | -1.85M | -2.22M | -657.00K |
| Cash from Financing | 23.06M | 24.38M | 25.02M | 24.98M | 2.79M |
| Foreign Exchange rate Adjustments | 578.00K | 343.00K | -39.00K | -50.00K | -177.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.46M | 25.26M | 24.54M | 20.39M | -14.74M |